Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics

Group 1 - Travere Therapeutics reported $81.73 million in revenue for Q1 2025, a year-over-year increase of 97.6% [1] - The EPS for the same period was -$0.47, improving from -$1.76 a year ago, with a surprise of +14.55% compared to the consensus estimate of -$0.55 [1] - The revenue exceeded the Zacks Consensus Estimate of $79.35 million, resulting in a surprise of +3.00% [1] Group 2 - Key metrics indicate that Travere's stock has returned +16% over the past month, while the Zacks S&P 500 composite has decreased by -0.7% [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance against the broader market in the near term [3] Group 3 - Revenue from Tiopronin products (Thiola) was $19.98 million, slightly below the average estimate of $20.90 million, representing a year-over-year change of -0.8% [4] - Total net product sales reached $75.86 million, exceeding the estimated $69.96 million [4] - Revenue from FILSPARI was $55.88 million, surpassing the average estimate of $49.31 million, with a year-over-year increase of +181.7% [4] - License and collaboration revenue was reported at $5.87 million, above the average estimate of $4.20 million, reflecting a year-over-year change of +322.4% [4]